2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
2
Lymphopenia
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Kidney Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
COVID-19
1
Breast Neoplasms
1
Interventions
Standard of Care
8
Surveys and Questionnaires
7
COVID-19 Vaccines
6
Blood Specimen Collection
6
BNT162 Vaccine
6
Specimen Handling
5
2019-nCoV Vaccine mRNA-1273
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Practice Guidelines as Topic
3
tocilizumab
2
sotrovimab
2
sinovac COVID-19 vaccine
2
cilgavimab and tixagevimab drug combination
2
Sodium Chloride
2
Pandemic Preparedness
2
Data Collection
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
Azithromycin
2
selinexor
1
remdesivir
1
regorafenib
1
proxalutamide
1
palbociclib
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Interleukin-7
×
Clear all
NCT04426201
2024-04-11
ILIAD-7-US-O
Revimmune
Phase 2
Terminated
10 enrolled